Market Overview

Aegis Capital Corp. Reiterates Buy Rating, $100 PT on Medivation

Related MDVN
In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated
Here Are All The Big Biotech Mergers In 2016
Biotech Forum Daily Digest: Mylan Adjusts Course, Who Is Next Midcap Buyout Target After Medivation? Spotlight On NeuroDerm (Seeking Alpha)

In a report published Wednesday, Aegis Capital Corp. reiterated its Buy rating and $100.00 price target on Medivation (NASDAQ: MDVN).

Aegis Capital noted, “Earlier today, it was disclosed that a California Superior Court judge had ruled last week against Medivation in the case of the firm vs. The Regents of The University of California (Case Number: CGC-11-510715). This case involved allegations by Medivation that a competing prostate cancer agent being developed by the privately-held firm Aragon Pharmaceuticals, ARN-509, actually belonged to Medivation. In our view, the decision may represent a perceptual setback but we note that Medivation is likely to appeal the decision, that a final resolution to this situation is likely to be a couple of years away, and that ARN-509, the competitor to Medivation's XTANDI™, is unlikely to reach the market for at least another four years. Data in chemotherapy-naive patients with XTANDI™ is scheduled to be released next year, and should enhance the competitive profile of the drug. Accordingly, we reiterate our Buy rating and maintain our 12-month price target of $100.00 per share on Medivation.”

Medivation closed on Monday at $50.03.

Latest Ratings for MDVN

Aug 2016BMO CapitalMaintainsMarket Perform
Aug 2016CitigroupDowngradesBuyHold
Aug 2016Credit SuisseDowngradesOutperformNeutral

View More Analyst Ratings for MDVN
View the Latest Analyst Ratings

Posted-In: Aegis Capital Corp.Analyst Color Reiteration Analyst Ratings


Related Articles (MDVN)

View Comments and Join the Discussion!